Variable | Missing data* | Overall in survivors | Women <75 years | Men <75 years | Women ≥75 years | Men ≥75 years | Cardiology | General medicine | Other |
Patients | 5499 | 727 | 1549 | 1583 | 1640 | 2588 | 2420 | 491 | |
Loop diuretic | 362 | 4744 (86%) | 625 (86%) | 1312 (85%) | 1372 (87%) | 1435 (88%) | 2229 (87%) | 2105 (87%) | 410 (84%) |
ACEI | 546 | 3400 (62%) | 462 (64%) | 1109 (72%) | 851 (54%) | 978 (60%) | 1728 (68%) | 1395 (58%) | 277 (56%) |
ARB | 966 | 716 (13%) | 101 (14%) | 197 (13%) | 235 (15%) | 183 (12%) | 343 (13%) | 317 (13%) | 56 (11%) |
ACEI or ARB | 4073 (74%) | 557 (77%) | 1289 (83%) | 1073 (68%) | 1154 (70%) | 2050 (79%) | 1692 (70%) | 331 (67%) | |
β-Blocker | 725 | 2760 (50%) | 400 (55%) | 993 (64%) | 621 (39%) | 746 (45%) | 1613 (63%) | 980 (40%) | 167 (34%) |
ARA | 794 | 1716 (31%) | 236 (32%) | 637 (41%) | 361 (23%) | 482 (29%) | 987 (38%) | 582 (24%) | 147 (30%) |
LVEF <40% | 3332 | 453 | 1174 | 696 | 1009 | 1920 | 1169 | 243 | |
Loop diuretic | 107 | 2899 (87%) | 384 (85%) | 999 (85%) | 624 (90%) | 892 (88%) | 1640 (85%) | 1053 (90%) | 206 (85%) |
ACEI | 258 | 2286 (69%) | 318 (70%) | 879 (75%) | 417 (60%) | 672 (67%) | 1353 (70%) | 780 (67%) | 153 (63%) |
ARB | 507 | 441 (13%) | 66 (15%) | 146 (12%) | 115 (17%) | 114 (11%) | 257 (13%) | 156 (13%) | 28 (12%) |
ACEI or ARB | 2701 (81%) | 381 (84%) | 1016 (87%) | 523 (75%) | 781 (77%) | 1595 (83%) | 926 (79%) | 180 (74%) | |
β-Blocker | 336 | 1971 (59%) | 285 (63%) | 797 (68%) | 345 (50%) | 544 (54%) | 1292 (67%) | 582 (50%) | 97 (40%) |
ARA | 386 | 1230 (37%) | 162 (36%) | 527 (45%) | 196 (28%) | 345 (34%) | 796 (41%) | 339 (29%) | 95 (39%) |
LVEF ≥40% | 937 | 128 | 169 | 407 | 233 | 364 | 465 | 108 | |
Loop diuretic | 34 | 824 (88%) | 117 (91%) | 137 (81%) | 357 (88%) | 213 (91%) | 324 (89%) | 405 (87%) | 95 (88%) |
ACEI | 118 | 472 (50%) | 67 (52%) | 102 (60%) | 191 (47%) | 112 (48%) | 193 (53%) | 220 (47%) | 59 (55%) |
ARB | 187 | 127 (14%) | 17 (13%) | 24 (14%) | 58 (14%) | 28 (12%) | 49 (13%) | 64 (14%) | 14 (13%) |
ACEI or ARB | 592 (63%) | 84 (66%) | 123 (73%) | 246 (60%) | 139 (60%) | 239 (66%) | 281 (60%) | 72 (67%) | |
β-Blocker | 152 | 381 (41%) | 61 (48%) | 95 (56%) | 135 (33%) | 90 (39%) | 178 (49%) | 163 (35%) | 40 (37%) |
ARA | 160 | 246 (26%) | 45 (35%) | 52 (37%) | 91 (22%) | 58 (25%) | 106 (29%) | 114 (25%) | 26 (24%) |
No LVEF report | 1230 | 146 | 206 | 480 | 398 | 304 | 786 | 140 | |
Loop diuretic | 221 | 1021 (83%) | 124 (85%) | 176 (85%) | 391 (81%) | 330 (83%) | 265 (87%) | 647 (82%) | 109 (78%) |
ACEI | 170 | 642 (52%) | 77 (53%) | 128 (62%) | 243 (51%) | 194 (49%) | 162 (53%) | 395 (50%) | 85 (61%) |
ARB | 272 | 148 (12%) | 18 (12%) | 27 (13%) | 62 (13%) | 41 (10%) | 37 (12%) | 97 (12%) | 14 (10%) |
ACEI or ARB | 780 (63%) | 92 (63%) | 150 (73%) | 304 (63%) | 234 (59%) | 197 (65%) | 485 (62%) | 98 (70%) | |
β-Blocker | 237 | 408 (33%) | 54 (37%) | 101 (49%) | 141 (30%) | 112 (28%) | 143 (47%) | 235 (30%) | 30 (21%) |
ARA | 248 | 240 (20%) | 29 (20%) | 58 (28%) | 74 (15%) | 79 (20%) | 85 (28%) | 129 (16%) | 26 (19%) |
Data are numbers (percentages) of the population surviving until discharge.
↵* Excluding 652 deaths on index admission and 20 patients with missing data on either sex, age or ward.
ACEI, ACE inhibitor; ARA, aldosterone receptor antagonist; ARB, angiotensin II receptor blocker; LVET, left ventricular ejection fraction.